Combined treatment (20 h) of GC-DLBCL (SU-DHL16), double-hit DLBCL cells (OCI-LY18, Carnaval) or ABC-DLBCL (HBL-1) resulted in increased caspase-3 cleavage but little change in the expression of BCL2, BCL-xL, or BIM (Fig. 3a). The gene discussed is BCL2L11; the disease is diffuse large B-cell lymphoma.